Patents by Inventor Adrian L. Gill

Adrian L. Gill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAS INHIBITORS
    Publication number: 20250242029
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 3, 2025
    Publication date: July 31, 2025
    Inventors: Elena S. KOLTUN, James Cregg, Yang Liu, Adrian L. Gill
  • RAS INHIBITORS
    Publication number: 20250195662
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 5, 2025
    Publication date: June 19, 2025
    Inventors: Elena S. KOLTUN, James CREGG, Yang LIU, Adrian L. GILL
  • RAS INHIBITORS
    Publication number: 20250197423
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: July 10, 2024
    Publication date: June 19, 2025
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, John E. KNOX, Yang LIU, G. Leslie BURNETT
  • RAS INHIBITORS
    Publication number: 20250186590
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: February 25, 2025
    Publication date: June 12, 2025
    Inventors: Elena S. KOLTUN, James CREGG, Yang LIU, Adrian L. GILL
  • RAS INHIBITORS
    Publication number: 20250154171
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: October 11, 2024
    Publication date: May 15, 2025
    Inventors: John E. KNOX, Elena S. KOLTUN, Jinyu LIU, Yang LIU, Benjamin D. MADEJ, Dylan E. PARSONS, Aidan TOMLINSON, Jingwei YIN, Georgios ALACHOUZOS, G.Leslie BURNETT, Neil CHAN, James CREGG, Anne V. EDWARDS, Adrian L. GILL
  • RAS INHIBITORS
    Publication number: 20250145643
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: July 3, 2024
    Publication date: May 8, 2025
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, John E. KNOX, Yang LIU, G. Leslie BURNETT
  • RAS INHIBITORS
    Publication number: 20250129097
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: December 9, 2024
    Publication date: April 24, 2025
    Inventors: James CREGG, Adrian L. Gill, Elena S. Koltun, John E. Knox
  • Ras inhibitors
    Patent number: 12280113
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: April 22, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: Elena S. Koltun, James Cregg, Yang Liu, Adrian L. Gill
  • Bicyclic heteroaryl compounds and uses thereof
    Patent number: 12258366
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: October 11, 2022
    Date of Patent: March 25, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • Ras inhibitors
    Patent number: 12252497
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: March 18, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, John E. Knox, Elena S. Koltun, Jennifer Pitzen, Christopher Semko
  • RAS INHIBITORS
    Publication number: 20250074923
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 14, 2024
    Publication date: March 6, 2025
    Inventors: John E. KNOX, Elena S. KOLTUN, Yang LIU, G. Leslie BURNETT, James CREGG, Anne V. EDWARDS, Adrian L. GILL, Andreas BUCKL, Christopher SEMKO
  • RAS INHIBITORS
    Publication number: 20250051306
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: February 29, 2024
    Publication date: February 13, 2025
    Inventors: James Aggen, G. Leslie Burnett, Jennifer Pitzen, Adrian L. Gill, Elena S. Koltun, James Cregg, Andreas Buckl, Anne V. Edwards, Christopher Semko, Micah James Gliedt, John E. Knox, William D. Thomas
  • Ras inhibitors
    Patent number: 12202845
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: January 21, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: John E. Knox, Elena S. Koltun, Yang Liu, G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, Andreas Buckl, Christopher Semko
  • RAS INHIBITORS
    Publication number: 20240400523
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 1, 2024
    Publication date: December 5, 2024
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Andreas BUCKL, John E. KNOX, Yang LIU
  • COVALENT RAS INHIBITORS AND USES THEREOF
    Publication number: 20240262847
    Abstract: The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 3, 2023
    Publication date: August 8, 2024
    Inventors: G. Leslie BURNETT, Anne V. EDWARDS, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Jennifer PITZEN
  • COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF
    Publication number: 20240139185
    Abstract: The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS-RAF inhibition, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 16, 2023
    Publication date: May 2, 2024
    Inventors: Meizhong JIN, Nicholas Perl, Anna Kohlmann, Ning Yin, Jason T. Lowe, Jae Young Ahn, Mark Joseph Mulvihill, Elena S. Koltun, Adrian L. Gill
  • Ras inhibitors
    Patent number: 11952352
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: April 9, 2024
    Assignee: Revolution Medicines, Inc.
    Inventors: Adrian L. Gill, James Cregg, Elena S. Koltun, Yang Liu
  • RAS INHIBITORS
    Publication number: 20230374035
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: February 6, 2023
    Publication date: November 23, 2023
    Inventors: Elena S. KOLTUN, James CREGG, Naing AAY, Andreas BUCKL, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Daniel M. WHALEN, John E. KNOX, Yang LIU
  • BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20230365605
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: October 11, 2022
    Publication date: November 16, 2023
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • RAS INHIBITORS
    Publication number: 20230303591
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: October 7, 2022
    Publication date: September 28, 2023
    Inventors: Andreas Buckl, G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, John E. Knox, Elena S. Koltun, Yang Liu, Christopher Semko